Last $63.87 USD
Change Today +0.16 / 0.25%
Volume 1.1M
ENDP On Other Exchanges
Symbol
Exchange
Berlin
Toronto
As of 1:30 PM 09/2/14 All times are local (Market data is delayed by at least 15 minutes).

endo international plc (ENDP) Snapshot

Open
$64.00
Previous Close
$63.71
Day High
$64.52
Day Low
$63.47
52 Week High
03/4/14 - $82.16
52 Week Low
09/3/13 - $41.04
Market Cap
9.8B
Average Volume 10 Days
1.3M
EPS TTM
$0.13
Shares Outstanding
153.5M
EX-Date
--
P/E TM
472.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for ENDO INTERNATIONAL PLC (ENDP)

endo international plc (ENDP) Related Businessweek News

View More BusinessWeek News

endo international plc (ENDP) Details

Endo International plc, a specialty healthcare company, develops, manufactures, markets, and distributes branded pharmaceutical and generic products, and medical devices worldwide. It provides branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar, and Fortesta Gel to treat and manage pain and conditions in urology, endocrinology, and oncology. The company also offers non-branded generic products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women’s health, and hypertension markets; and pharmaceutical products in the areas of ADHD, pain, urology, and allergy. In addition, it provides various medical devices comprising AMS 700 MS series, AMS 800 artificial urinary sphincters, GreenLight XPS laser systems, Elevate anterior and posterior pelvic floor repair systems, and Monarc subfascial hammock products in the areas of men’s and women’s health, and prostate health. The company’s products also include Aveed, an injectable testosterone preparation to treat male hypogonadism; and BEMA Buprenorphine, a transmucosal form of buprenorphine in Phase III trials for treating moderate to severe chronic pain. It serves pharmacy chains directly; and hospitals, governmental agencies, pharmacies, and physicians through wholesale drug distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

endo international plc (ENDP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $4.3M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $157.0K
Chief Legal Officer, Executive Vice President...
Total Annual Compensation: $562.0K
Chief Operating Officer of Pharmaceuticals
Total Annual Compensation: $270.8K
Compensation as of Fiscal Year 2013.

endo international plc (ENDP) Key Developments

American Medical Reported Updates On Sale

American Medical Sytems, Inc. has been put up for sale by Endo International plc (NasdaqGS:ENDP) and private equity firms are among the prospective buyers courting it for as much as $2 billion, The Wall Street Journal reports, citing people familiar with the matter.

American Medical Sytems, Inc. Reportedly Up For Sale

Endo International plc (NasdaqGS:ENDP) has put American Medical Sytems, Inc. Up For Sale, according to people familiar with the matter.

Endo International plc Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Raises Earnings Guidance for 2014

Endo International plc reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, total revenues were $718.684 million against $712.148 million a year ago. Net income was $21.160 million or $0.13 per diluted share against $34.999 million or $0.30 per diluted share a year ago. Adjusted net income was $173.682 million or $1.06 per diluted share against $166.348 million or $1.42 per diluted share a year ago. Operating income was $104.590 million against $96.395 a year ago. Adjusted operating income was $271.597 million against $281.955 million a year ago. Income from continuing operation before tax was $39.148 million against $70.761 million a year ago. Adjusted income from continuing operation before tax was $225.740 million against $244.390 million a year ago. Income from continuing operation was $23.554 million or $0.15 per diluted share against $41.749 million or $0.36 per diluted share a year ago. Adjusted income from continuing operation was $174.657 million or $1.06 per diluted share against $164.544 million or $1.40 per diluted share a year ago. For the six months, total revenues were $1,313.293 million against $1,370.642 million a year ago. Net loss was $415.752 million or $2.96 per diluted share against net income of $50.348 million or $0.44 per diluted share a year ago. Adjusted net income was $307.747 million or $1.99 per diluted share against $289.586 million or $2.51 per diluted share a year ago. Operating loss was $492.566 million against operating income of $164.617 a year ago. Adjusted operating income was $491.017 million against $491.885 million a year ago. Loss from continuing operation before tax was $614.970 million against income from continuing operation before tax of $101.664 million a year ago. Adjusted income from continuing operation before tax was $403.763 million against $414.536 million a year ago. Loss from continuing operation was $415.143 million or $2.96 per diluted share against income from continuing operation of $63.402 million or $0.55 per diluted share a year ago. Adjusted income from continuing operation was $307.747 million or $2.00 per diluted share against $288.882 million or $2.51 per diluted share a year ago. Net cash used in operating activities was $52.631 million against net cash provided by operating activities of $117.031 million a year ago. Purchases of property, plant and equipment, net was $40.379 million against $37.029 million a year ago. For the full year of 2014, the company raises expected 2014 revenues to a range from $2.72 billion to $2.80 billion and raises expected 2014 adjusted diluted EPS to a range from $3.80 to $4.00. The company expects reported diluted (GAAP) loss per share to be in the range from $1.77 to $1.57. Adjusted effective tax rate of between 23% and 24%.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENDP:US $63.87 USD +0.16

ENDP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ENDP.
View Industry Companies
 

Industry Analysis

ENDP

Industry Average

Valuation ENDP Industry Range
No financial data is available for ENDP.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENDO INTERNATIONAL PLC, please visit www.endo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.